Congress considered proposals to strengthen FDA authority regarding medical device regulation and minimum standards.
Steady: 0 in the last 7 days
Updated oct 21
The latest in this situation
- Congress and the Senate are considering legislation affecting FDA submissions and drug patent rights.
- The government launched a new dental care program under the leadership of Justin Trudeau's government, involving the Canadian Dental Association.
- Co-sponsoring the bill to restrict corporate practice of medicine.
- New legislation restricting corporate healthcare decisions was supported by Senators Jeff Merkley and Ron Wyden.
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Congress considered proposals to strengthen FDA authority regarding medical device regulation and minimum standards.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.Sub-event
- Calls are being made for enhanced informed consent laws, which are being discussed in the form of proposed legislative bills in Michigan.Sub-event
- Bills were introduced in the House and Senate to address agency modernization and public health standards.Sub-event
- A bill was introduced on July 17th to strengthen oversight of the FDA, involving Ron Wyden.Sub-event
Congress debated proposals to strengthen FDA's authority over medical devices.1 source
FDA actions and withdrawal occurred during state legislative activity, affecting calls for stronger regulation.1 source
Keep exploring
The entities involved
Related events
- AMA urges FDA to maintain standards as federal government implements marijuana rescheduling order amid GAO findings of regulatory deficiencies.
- ISO standards are influencing regulatory requirements across the industry.
- FDA, LabCorp, and Charles River Laboratories formed a collaboration to evaluate the potential for medicine abuse.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA confirmed CMC and device plans are Phase 3 ready, coinciding with strengthening of US and EU patent estates.
Coverage
Newest first; wire copies grouped- fda.gov
- healio.com
- Zacks3 Top Medical Instruments Stocks Defying Tariff Pressure With GenAI Over the past year, the Medical Instruments industry has seen the transition of generative AI (genAI) from experimental to operatio